2013Dr. Jan-Michael Peters is appointed new Scientific Director of the IMP, Prof. Meinrad Busslinger succeeds him as Deputy Director. Former IMP-Director Barry Dickson accepts a call to the Janelia Farm Research Campus of the Howard Hughes Medical Institute, USA.


A new campus wide scientific core facility with a broad range of new technologies is set up with support from the City of Vienna and the Ministry of Science.

2008The IMP celebrates its 20th Anniversary. The highlight of the anniversary was a scientific conference in the Hofburg Conference Centre with outstanding speakers and personalities from the IMP both past and present. 
2006Official Opening of the "Austrian Academy of Sciences - Life Sciences Center Vienna" next door, home to the Gregor Mendel Institute of Molecular Plant Biology (GMI), the Institute of Molecular Biotechnology (IMBA) and the expanded core facilities.
2006Dr. Barry Dickson is appointed as new Scientific Director after Kim Nasmyth accepted the Whitley chair at the university of Oxford.
2004A Shared-Services agreement ("IMP-IMBA Research Center") with the Institute of Molecular Biotechnology (IMBA) is set up.
2002Researchers of the newly founded Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) start working preliminary in the IMP building.
1998The biotech company Intercell is founded as spin-off by Max Birnstiel and colleagues from the IMP and the University of Vienna.
1997Prof. Kim Nasmyth, Senior Scientist at the IMP, takes over as Scientific Director of the IMP after the retirement of Max Birnstiel.
1993Founding of the International PhD Program. Through this program, PhD students are selected among highly qualified applicants from all over the world and are given the opportunity for training and work in different areas at the forefront of modern biology. Today the Vienna Biocenter PhD Programme is organized jointly by the IMP, the Max F. Perutz Laboratories (MFPL), the Institute of Molecular Biotechnology (IMBA) and the Gregor Mendel Institute (GMI).
1993Boehringer Ingelheim takes over all shares of the IMP.
1992The University of Vienna opens a new research building next door. Together with the IMP it forms the basis of the newly founded "Campus Vienna Biocenter".
1988Relocation to the newly renovated building in Dr. Bohr-Gasse 7, 3rd district of Vienna

The molecular biologist Max Birnstiel, professor at the University of Zurich, is appointed Scientific Director of the IMP. Recruiting of the first Group Leaders and Senior Scientists starts.

1985Founding of the IMP as a joint research center of the pharmaceutical company Boehringer Ingelheim (Germany) und the biotech-company Genentech (US).